36 results on '"Manojlovic, Nebojsa"'
Search Results
2. Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer
3. Dynamic monitoring of carcinoembryonic antigen, CA19-9 and inflammation-based indices in patients with advanced colorectal cancer undergoing chemotherapy
4. Seroreactivity against Helicobacter pylori VacA,50kDa and 30kDa along with alarm features may improve the diagnostic approach to uninvestigated dyspepsia: A pilot study
5. Perioperative bevacizumab in the treatment of colorectal cancer in patients with liver metastases
6. Simultaneous and alternative IgG seroreactivity against Helicobacter pylori antigens VacA ,30 kDa and 50 kDa is a better biomarker approach for the outcome of infection than VacA and 50 kDa alone
7. The Usefulness of Prognostic Nutritional Index in Predicting Infection in Patients with Newly Diagnosed Pancreatic Cancer
8. Namodenoson in Advanced Hepatocellular Carcinoma and Child–Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial
9. Prognostic factors in patients with advanced colorectal cancer receiving systemic chemotherapy
10. Helicobacter pylori infection in patients with non gastric non Hodgkinʼs lymphoma
11. Serum IgG antibodies against Helicobacter pylori low molecular weight antigens 50kDa, 30kDa and Urease A 26 kDa, along with vacuolating cytotoxin A are associated with the outcome of the infection
12. A phase II, randomized, double-blind, placebo-controlled trial evaluating efficacy and safety of namodenoson (CF102), an A3 adenosine receptor agonist (A3AR), as a second-line treatment in patients with Child-Pugh B (CPB) advanced hepatocellular carcinoma (HCC).
13. Antiplatelet agents'-ticagrelol and eptifibatide-safety in experimental colitis in mice.
14. Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer
15. Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx®) : a placebo-controlled randomised phase II study (PLIANT)
16. Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx®): a placebo-controlled randomised phase II study (PLIANT)
17. Early tumor shrinkage (ETS) and depth of response (DpR) in wild-type (WT) RAS tumors from the phase III trial of panitumumab (pmab) plus best supportive care (BSC) versus BSC in chemorefractory metastatic colorectal cancer (mCRC).
18. A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer
19. Association of ECOG performance status with efficacy in patients receiving panitumumab with best supportive care (BSC) vs BSC alone for chemorefractory metastatic colorectal cancer.
20. Final results from a phase III trial evaluating panitumumab (pmab) + best supportive care (BSC) vs BSC in chemorefractory wild-type (WT) KRAS exon 2 and WT RAS metastatic colorectal cancer (mCRC).
21. Persistent prevention of CIPN using calmangafodipir (PledOx): Results from a placebo-controlled randomized phase II study (PLIANT) in patients with metastatic colorectal cancer (mCRC).
22. Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer.
23. An open label, randomized phase III trial evaluating the treatment (tx) effects of panitumumab (pmab) + best supportive care (BSC) versus BSC in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) and in WT RAS mCRC.
24. Phase II randomized trial of MEK inhibitor pimasertib or placebo combined with gemcitabine in the first-line treatment of metastatic pancreatic cancer.
25. Conversion-To-Resectability Chemotherapy for Liver Metastases of Colorectal Cancer: Updated Results of Relevant Multicenter Trial
26. Safety of Capecitabine in Treatment of Patients with Metastatic Colorectal Cancer – Interim Analysis From “Axiom” Trial
27. Clamp-Crushing vs. Radiofrequency-Assisted Liver Resection: Changes in Liver Function Tests
28. Efficacy and safety of bevacizumab in combination with oxaliplatin, irinotecan and fluoropyrimidine-based therapy in advanced colorectal cancer
29. Localization, clinical and pathological characteristics of the colon cancer patients aged up to 40 years and over 65 years
30. P-0246 - Conversion-To-Resectability Chemotherapy for Liver Metastases of Colorectal Cancer: Updated Results of Relevant Multicenter Trial
31. P-0250 - Safety of Capecitabine in Treatment of Patients with Metastatic Colorectal Cancer – Interim Analysis From “Axiom” Trial
32. Clamp-crushing vs. radiofrequency-assisted liver resection:changes in liver function tests.
33. Capecitabine cardiotoxicity--case reports and literature review.
34. Anti Helicobacter pylori IgG and IgA response in patients with gastric cancer and chronic gastritis.
35. Radiation-induced rectal ulcer--prognostic factors and medical treatment.
36. Systemic humoral anti-Helicobacter pylori immune response in patients with gastric malignancies and benign gastroduodenal disease.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.